Literature DB >> 8706007

Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases.

J P Gibbs1, M Czerwinski, J T Slattery.   

Abstract

We have examined the catalytic activity of glutathione S-transferases (GST) in the conjugation of busulfan with glutathione (GSH) in human liver cytosol, purified human liver GST, and cDNA-expressed GST-alpha 1-1. Human liver microsomes and cytosol were incubated with 40 microM busulfan and 1 mM GSH. Cytosol catalyzed the formation of the GSH-busulfan tetrahydrothiophenium ion (THT+) in a concentration-dependent manner, whereas microsomes lacked activity. The total and spontaneous rates of THT+ formation increased with pH (pH range, 6.50-7.75), with the maximum difference at pH 7.4. Due to the limited aqueous solubility of busulfan, a K(m) for busulfan was not determined. The intrinsic clearance (Vmax/K(m)) of busulfan conjugation was 0.167 microliter/min/mg with 50-1200 microM busulfan and 1 mM GSH. GSH Vmax and K(m) for busulfan conjugation were 30.6 pmol/min/mg and 312 microM, respectively. Ethacrynic acid (0.03-15 microM) inhibited cytosolic busulfan-conjugating activity with 40 microM busulfan and 1 mM GSH. Enzyme-mediated THT+ formation was decreased 97% by 15 microM ethacrynic acid with no effect on the spontaneous reaction. In incubations with affinity-purified liver GST and GST-alpha 1-1, the intrinsic clearance for busulfan conjugation was 0.87 and 2.92 microliters/min/mg, respectively. Busulfan is a GST substrate with a high K(m) relative to concentrations achieved clinically (1-8 microM).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8706007

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  Metabolism of the cysteine S-conjugate of busulfan involves a beta-lyase reaction.

Authors:  Arthur J L Cooper; Islam R Younis; Zoya V Niatsetskaya; Boris F Krasnikov; John T Pinto; William P Petros; Patrick S Callery
Journal:  Drug Metab Dispos       Date:  2008-05-12       Impact factor: 3.922

2.  The Myeloablative Drug Busulfan Converts Cysteine to Dehydroalanine and Lanthionine in Redoxins.

Authors:  Michele Scian; Miklos Guttman; Samantha D Bouldin; Caryn E Outten; William M Atkins
Journal:  Biochemistry       Date:  2016-08-11       Impact factor: 3.162

3.  Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation.

Authors:  Francesca Bonifazi; Gianluca Storci; Giuseppe Bandini; Elena Marasco; Elisa Dan; Elena Zani; Fiorenzo Albani; Sara Bertoni; Andrea Bontadini; Sabrina De Carolis; Maria Rosaria Sapienza; Simonetta Rizzi; Maria Rosa Motta; Martina Ferioli; Paolo Garagnani; Michele Cavo; Vilma Mantovani; Massimiliano Bonafè
Journal:  Haematologica       Date:  2013-09-20       Impact factor: 9.941

Review 4.  Interactions between antiretrovirals and antineoplastic drug therapy.

Authors:  Tony Antoniou; Alice L Tseng
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Prediction of Intravenous Busulfan Clearance by Endogenous Plasma Biomarkers Using Global Pharmacometabolomics.

Authors:  Yvonne S Lin; Savannah J Kerr; Timothy Randolph; Laura M Shireman; Tauri Senn; Jeannine S McCune
Journal:  Metabolomics       Date:  2016-09-15       Impact factor: 4.290

Review 6.  Plasma concentration monitoring of busulfan: does it improve clinical outcome?

Authors:  J S McCune; J P Gibbs; J T Slattery
Journal:  Clin Pharmacokinet       Date:  2000-08       Impact factor: 6.447

7.  Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients.

Authors:  Nissa Abbasi; Barbara Vadnais; Jennifer A Knutson; David K Blough; Edward J Kelly; Paul V O'Donnell; H Joachim Deeg; Matthew A Pawlikowski; Rodney J-Y Ho; Jeannine S McCune
Journal:  J Clin Pharmacol       Date:  2010-12-06       Impact factor: 3.126

8.  Overexpression of glutathione S-transferase A1-1 in ECV 304 cells protects against busulfan mediated G2-arrest and induces tissue factor expression.

Authors:  Christoph A Ritter; Bernhard Sperker; Markus Grube; Dana Dressel; Christiane Kunert-Keil; Heyo K Kroemer
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 9.  Reversible and irreversible protein glutathionylation: biological and clinical aspects.

Authors:  Arthur Jl Cooper; John T Pinto; Patrick S Callery
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-05-11       Impact factor: 4.481

10.  Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients.

Authors:  Christa E Nath; John W Earl; Nalini Pati; Katherine Stephen; Peter J Shaw
Journal:  Br J Clin Pharmacol       Date:  2008-03-13       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.